1 / 36

Chronic renal failure from lead: myth or evidence-based fact?

Chronic renal failure from lead: myth or evidence-based fact?. Kidney International (2011) 79, 272–279 F1 陳筱惠 指導醫師：尤俊成醫師. Lead poisoning: Blood lead levels (PbB) > 80 ug/dl Anemia, colic pain, peripheral neuropathy, encephalopathy, nephropathy and chronic renal failure (CRF)

cirila
Télécharger la présentation

Chronic renal failure from lead: myth or evidence-based fact?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chronic renal failure from lead: myth or evidence-based fact? Kidney International (2011) 79, 272–279 F1陳筱惠 指導醫師：尤俊成醫師

  2. Lead poisoning: • Blood lead levels (PbB) > 80 ug/dl • Anemia, colic pain, peripheral neuropathy, encephalopathy, nephropathy and chronic renal failure (CRF) • Cardiovascular mortality and high blood pressure

  3. The epidemiological and pathophysiological evidence of lead exposure as a risk factor for the development of CRF? • Searched database: PubMed • Keywords: ‘lead’, ‘nephrotoxicity’, ‘epidemiologic’, ‘experimental’, ‘kidney disease, chronic’, and ‘renal’

  4. HUMAN EXPOSURE AND ACCUMULATION OF LEAD • Lead enters the human body by ingestion or inhalation. • Data from the National Health and Nutrition Examination Survey study in the United States: a decline in the geometric mean PbB level in the general population from 13.1 ug/dl in 1976–1988 to 1.6 ug/dl in 1999–2002

  5. Factors that have been linked to higher PbB: older age, male sex, lead in old paint and water pipes, smoking, moonshine drinking, lower socioeconomic status, urban residence, and housing in older buildings

  6. 95% of the absorbed lead is stored in the bones of adults • Half life: 4–20 years • Cortical bone > trabecular bone • The clinical importance of the stored lead is not clear  an endogenous source of lead in plasma

  7. PbB : <5% free in the plasma, and the rest bound to the erythrocytes (the enzyme d-aminolevulinic acid, ALAD) • Half life: 30 days • The exchange of lead is greater during increased bone turnover such as pregnancy, immobilization, or hyperparathyroidism.

  8. BIOMARKERS OF LEAD EXPOSURE • PbB: on-going exposure • Affected by higher bone turnover, acidosis, and inflammation • Lead burden: mobilization test using a chelating agent • Intramuscular or intravenous administration of CaNa2 EDTA • Lead–EDTA complex in the urine during the following 24h, >600 ug excreted lead/24h)

  9. In patients with CRF, the urinary elimination of the lead–EDTA complex is delayed 72h • The sensitivity and specificity of the EDTA diagnostic test in the levels of patients below the toxic limit (<600 ug/72 h), especially in patients with different glomerular filtration rates (GFRs) are uncertain.

  10. In vivo X-ray fluorescence: • Poor sensitivity and specificity compared with the EDTA diagnostic test among CRF patients

  11. GENERAL TOXICITY OF LEAD • Inactivation of ALAD enzyme systems by binding to sulfhydryl groups • Accumulation of aminolevulinic acid and zinc protoporphyrin in blood, plasma, and urine • Interference with heme biosynthesis

  12. COMMONLY DESCRIBED RENAL EFFECTS FROM LEAD • The classical lead nephropathy exhibited at toxic levels: • Minimal proteinuria, a benign urinary sediment, hyperuricemia, and often hypertension • Glomerular hyperfiltration: • Rats fed with lead increased their GFR at 3 months compared with control rats, but had lower GFR at 6 and 12 months.

  13. Chelate treatment improved GFR both among lead-fed rats and among control rats and reduced the morphological changes seen after lead exposure was discontinued.

  14. The kidneys are granular and contracted. • Renal biopsies: • The glomeruli are sclerotic. • The arterioles often show intima proliferation and hyaline degeneration of the media. • Tubular atrophy and interstitial fibrosis without cellular infiltration

  15. Proximal tubules: acid-fast nuclear inclusion bodies, consisting of a lead–protein-binding complex, observed during the initial phases of acute lead exposure, and rarely at later stages

  16. ENVIRONMENTALLY EXPOSED POPULATIONS ANDINDICATORS OF RENAL EFFECTS • Most of the general population studies are also cross-sectional. • The majority of the studies with renal function outcomes use S-Cr or creatinine clearance, whereas some studies used cystatin C. • The mean PbB levels ranged between 2.2 and 43.5 ug/dl. • Most of these studies showed an association between higher PbB and lower creatinine clearance or estimated GFR.

  17. Continued decline in blood lead levels among adults in the United States. Arch Intern Med 2005; 165: 2155–2161 • People in the highest quartile of PbB (>=2.47 ug/dl) were 2.72 times more likely to have chronic kidney disease stage 3 or less based on estimated GFR compared with the lowest quartile (<1.06 ug/dl). • Hypothesis  causative association??

  18. RENAL EFFECTS IN ENVIRONMENTALLY EXPOSED CHILDREN • An investigation of the extraordinary incidence of chronic nephritis in young people in Queensland. Med J Aust 1929; 2: 145–159 • High frequency of childhood plumbism  high incidence of young people with chronic nephritis • However, the relationship between childhood lead intoxication and chronic nephritis has been difficult to confirm.

  19. 2 recent studies on adolescents show the same positive cross-sectional relationship between PbB and cystatin C or S-Cr observed among adults. • Blood lead level and kidney function in US adolescents. Arch Intern Med 2010; 170: 75–82. • A longitudinal study of the effects of long-term exposure to lead among lead battery factory workers in Taiwan (1989–1999). Sci Total Environ 2001; 279: 151–158.

  20. Renal function 17 to 23 years after chelation therapy for childhood plumbism. Kidney Int 1992; 42: 1226–1231 • No significant difference in elevation of serum creatinine (S-Cr), proteinuria, or blood pressure after 17–23 years compared with sibling controls • A 50-year follow-up of childhood plumbism: hypertension, renal function, and hemoglobin levels among survivors. AJDC 1991; 145: 681–687 • No significant difference in S-Cr compared with controls, but the exposed subjects had higher creatinine clearance and higher blood pressure

  21. OCCUPATIONAL LEAD EXPOSURE AND CRF • Since 1985, 19 reports, all cross-sectional studies

  22. In spite of all that has been reported on the effects from acute or ongoing excessive exposure, there are only a few of the studies presented in Table in which the GFR is significantly reduced. • The approximate frequency of CRF (GFR < 60 ml/min) from these observations is 1.5% almost identical to the population prevalence of stage 3 chronic kidney disease (1.4%) among 40- to 59-year-old subjects

  23. Longitudinal associations between lead dose and renal function in lead workers. Environ Res 2009;109: 101–107. • 537 lead workers followed for 42.1 years showed no general effect of PbB (mean baseline 31.3 mg/dl) on creatinine clearance.

  24. Occupational lead exposure and severe CKD: a population-based case-control and prospective observational cohort study in Sweden. Am J Kidney Dis 2010; 55: 497–506. • Not find a more rapid decline in the estimated GFR during 5–7 years among patients occupationally exposed to lead compared with those non-exposed. • Neither was renal survival significantly decreased (hazard ratio 0.92 (95% confidence interval 0.7–1.2) for ever exposed participants compared with never-exposed)

  25. LEAD EXPOSURE AND CRF OUTCOMES • Only 4 case–control studies: no association • New occupational risk factors for chronic renal failure. Lancet 1995; 346: 7–11 • Odds ratio (OR) for CRF associated with lead exposure was 2.1 (95% confidence interval 1.2–4.4)

  26. Association of tibia lead and blood lead with end-stage renal disease: a pilot study of African Americans. Environ Res 2007; 104: 396–401 • The OR for end-stage renal disease associated with tibia lead > 20 ug/g was 1.6 (95% confidence interval 0.6–4.4)

  27. A higher lead burden measured by the EDTA diagnostic test is associated with a more rapid deterioration rate in CRF patients of different etiologies • The patients treated with repeated chelate therapy progressed slower than those who did not receive any treatment. • Confounding factors, such as acidosis, inflammation, and hyperparathyroidism, were not measured • Patients were followed only through S-Cr.

  28. DISCUSSION • In the occupational studies, in which individuals had been exposed to lead at high levels for many years giving rise to PbB >60 ug/dl or an EDTA test diagnostic test >600 ug/24h, there is possibly a risk of developing acute lead nephropathy • CRF or end-stage renal disease?? • In Europe, the number of individuals with lead nephropathy as a reported causes of ESRD  7/143,733

  29. The possible effect from lead exposure on the progression of kidney disease?? • The very few longitudinal studies on exposed workers have not supported a deteriorating renal function except in some risk populations of patients with diabetes or hypertension. • Animal studies have also failed to demonstrate reliable evidence for a long-term effect on the glomerular function when lead levels are below toxic. • Hyperfiltration  kidney damage

  30. Selection bias in occupational studies ?? • Healthy worker effect: workers are generally healthier compared with the general population  If workers with early signs of renal function loss were removed from the work force • Screen for kidney failure on a regular basis

  31. Positive associations between PbB and S-Cr; Whether there is causality?? • PbB is elevated CRF patients. • Altered bioavailability, acidosis, malnutrition, inflammation, disturbed bone and mineral metabolism, and hyperparathyroidism  increase the decline in GFR

  32. The old ‘fact’ ?? • Well-controlled longitudinal studies with adequate exposure and effect variables; experimental evidence • Biomarkers of lead exposure among patients with renal failure • More precise measurements of the GFR than p-creatinine

  33. Thanks for your listening

More Related